108 related articles for article (PubMed ID: 27959765)
21. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
22. Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma.
Funato K; Smith RC; Saito Y; Tabar V
Cell Stem Cell; 2021 May; 28(5):894-905.e7. PubMed ID: 33631117
[TBL] [Abstract][Full Text] [Related]
23. Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
Nazem A; Lavezo J; Abdullaev Z; Aldape K; Quezado M; Cimino PJ; Pratt DW; Jenkins RB; Ida CM
J Neuropathol Exp Neurol; 2023 Dec; 83(1):58-60. PubMed ID: 37878797
[No Abstract] [Full Text] [Related]
24. Correlation of p53 immunoreactivity and sequencing in patients with glioma.
Kyritsis AP; Xu R; Bondy ML; Levin VA; Bruner JM
Mol Carcinog; 1996 Jan; 15(1):1-4. PubMed ID: 8561860
[TBL] [Abstract][Full Text] [Related]
25. [Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis].
Sarma PP; Dutta D; Mirza Z; Saikia KK; Baishya BK
Mol Biol (Mosk); 2017; 51(2):334-341. PubMed ID: 28537240
[TBL] [Abstract][Full Text] [Related]
26. Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas.
Mueller W; Lass U; Wellmann S; Kunitz F; von Deimling A
Acta Neuropathol; 2005 Mar; 109(3):314-20. PubMed ID: 15668788
[TBL] [Abstract][Full Text] [Related]
27. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
[TBL] [Abstract][Full Text] [Related]
28. Malignant progression of a histone H3.3 K27M-mutated spinal pilocytic astrocytoma in an adult.
Reers S; Krug D; Stummer W; Hasselblatt M
Clin Neuropathol; 2017; 36 (2017)(2):83-85. PubMed ID: 27900936
[No Abstract] [Full Text] [Related]
29. Ethnicity delineates different genetic pathways in malignant glioma.
Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
[TBL] [Abstract][Full Text] [Related]
30. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
31. High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord.
Gessi M; Gielen GH; Dreschmann V; Waha A; Pietsch T
Acta Neuropathol; 2015 Sep; 130(3):435-7. PubMed ID: 26231952
[No Abstract] [Full Text] [Related]
32. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
33. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
34. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
35. TP53 mutations but no CHEK2 *1100DelC variant in familial gliomas.
El Hallani S; Boisselier B; Marie Y; Paris S; Idbaih A; Carpentier C; Hoang-Xuan K; Delattre JY; Sanson M
Cancer Genet Cytogenet; 2009 Jan; 188(2):126-8. PubMed ID: 19100519
[No Abstract] [Full Text] [Related]
36. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
37. TP53 promoter methylation in human gliomas.
Amatya VJ; Naumann U; Weller M; Ohgaki H
Acta Neuropathol; 2005 Aug; 110(2):178-84. PubMed ID: 16025287
[TBL] [Abstract][Full Text] [Related]
38. [Aberrant expression of sox2 gene in malignant gliomas].
Volnitskiĭ AV; Semenova EV; Shtam TA; Kovalev RA; Filatov MV
Tsitologiia; 2014; 56(7):504-10. PubMed ID: 25696994
[TBL] [Abstract][Full Text] [Related]
39. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
40. A study on the correlation between STAT‑1 and mutant p53 expression in glioma.
Yang W; Wang H; Ju H; Dou C
Mol Med Rep; 2018 Jun; 17(6):7807-7812. PubMed ID: 29620180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
